wilate prophylaxis expanded to pediatric von Willebrand disease

What this means

Wilate is a clotting factor treatment that replaces missing proteins to help prevent bleeding in people with von Willebrand disease, a genetic disorder that impairs blood clotting. Today FDA expanded Wilate's approval to include children for routine prophylaxis to prevent bleeding episodes. The agency advises healthcare professionals to "monitor patients for hypersensitivity reactions and thromboembolic events" when using Wilate.